Breo Ellipta fluticasone/vilanterol

Insurance-forced discontinuation, not clinical failure, is the single largest preventable adherence leak for Breo Ellipta, and patients who survive the first 6 weeks become its strongest advocates.

• Once-daily convenience and dramatic breathing improvement drive fierce loyalty among long-term COPD patients, but asthma patients experience a steep, early side-effect cliff that triggers rapid discontinuation.
• Insurance coverage loss or unaffordable out-of-pocket costs are cited in roughly one-in-three positive-experience narratives as the reason patients stopped Breo despite it working well for them.
• Neuropsychiatric side effects including severe anxiety, insomnia, heart palpitations, and mood disturbance are disproportionately reported by asthma patients and are rarely flagged proactively by prescribers.
• Device technique confusion and uncertainty about whether a full dose was inhaled surface repeatedly, aligning with the FAERS signal on wrong-technique events and representing a solvable onboarding gap.